P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl.
Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward W, Reuben J, Hortobagyi G, Ueno N. P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl. Cancer Research 2011, 71: p2-02-01-p2-02-01. DOI: 10.1158/0008-5472.sabcs11-p2-02-01.Peer-Reviewed Original ResearchInflammatory breast cancerReceptor tyrosine kinase AXLTIG1 expressionTyrosine kinase AXLBreast cancerSUM149 cellsTumor growthEffective standard therapyNon-IBC cell linesPrognosis of patientsTreatment of patientsMammary fat padMatrix metalloproteinase-9Athymic nude miceIBC cell linesCell linesIBC cellsStandard therapyGene 1 expressionMolecular mechanismsDownregulation of expressionAxl expressionClinical subtypesMetalloproteinase-9Malignant processGene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet 2011, 378: 1812-1823. PMID: 22098854, DOI: 10.1016/s0140-6736(11)61539-0.Peer-Reviewed Original ResearchConceptsBreast cancerER-negative breast cancerGene expression profilingER-positive diseasePrognosis of patientsDistinct molecular aberrationsMolecular classification systemPotential clinical useClinical behaviorHistological featuresClinical trialsMolecular subtypesProliferation-related genesMultigene classifiersClinical practiceMolecular aberrationsExpression profilingCancerDistinct diseasesMultigene predictorsClinical useMolecular classificationDiseaseHeterogeneous groupDifferent diseases